International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(19), С. 14679 - 14679
Опубликована: Сен. 28, 2023
In
the
last
few
decades,
RNA-based
drugs
have
emerged
as
a
promising
candidate
in
treatment
of
various
diseases.
The
introduction
messenger
RNA
(mRNA)
vaccine
or
therapeutic
agent
enables
production
almost
any
functional
protein/peptide.
key
to
applying
therapy
clinical
trials
is
developing
safe
and
effective
delivery
systems.
Exosomes
lipid
nanoparticles
(LNPs)
been
exploited
vehicles
for
drug
delivery.
This
review
discusses
feasibility
exosomes
LNPs
mRNA
Cancer/testis
antigens
(CTAs)
show
restricted
expression
normal
tissues
widespread
cancer
tissues.
Many
these
CTAs
sera
patients
with
cancers.
These
characteristics
make
them
excellent
targets
immunotherapy.
summarizes
roles
life
processes
current
studies
on
mRNAs
encoding
CTAs.
Clinical
present
beneficial
effects
highlight
employing
mRNA-LNPs
Pharmaceutics,
Год журнала:
2023,
Номер
15(10), С. 2491 - 2491
Опубликована: Окт. 19, 2023
This
study
presents
the
synthesis
of
glucosamine-modified
mesoporous
silica-coated
magnetic
nanoparticles
(MNPs)
as
a
therapeutic
platform
for
delivery
an
anticancer
drug,
methotrexate
(MTX).
The
MNPs
were
coated
with
silica
in
templated
sol-gel
process
to
form
MNP@MSN,
and
then
chloropropyl
groups
added
structure
post-modification
reaction.
Glucosamine
was
reacted
chloro-modified
structure,
conjugated
hydroxyl
group
glucose.
prepared
characterized
using
techniques
such
Fourier
transform
infrared
(FT-IR)
spectroscopy,
elemental
analysis
(CHN),
field
emission
scanning
electron
microscopy
(FESEM),
transmission
(TEM),
dynamic
light
scattering
(DLS),
vibrating
sample
magnetometer
(VSM),
X-ray
diffraction
(XRD).
Good
formation
nano-sized
MNP@MSN
observed
via
particle
size
monitoring.
modified
glucosamine
showed
controlled
release
profile
simulated
tumor
fluid.
In
vitro
evaluation
4T1
breast
cancer
cell
line
cytotoxicity,
apoptosis,
cycle
effects
methotrexate.
MTT
assay
comparable
toxicity
between
MTX-loaded
free
MTX.
could
act
glucose
transporter-targeting
agent
increased
uptake
cells.
An
vivo
model
established
BALB/C
mice,
distribution
MTX-conjugated
particles
visualized
MRI.
significant
anti-tumor
potential
together
MRI
contrast
enhancement.
Journal of Nanobiotechnology,
Год журнала:
2024,
Номер
22(1)
Опубликована: Июнь 18, 2024
Abstract
The
use
of
nanomaterials
in
gene
editing
and
synthetic
biology
has
emerged
as
a
pivotal
strategy
the
pursuit
refined
treatment
methodologies
for
pulmonary
disorders.
This
review
discusses
utilization
nanomaterial-assisted
tools
techniques
to
promote
development
more
precise
efficient
treatments
diseases.
First,
we
briefly
outline
characterization
respiratory
system
succinctly
describe
principal
applications
diverse
lung
ailment
treatment.
Second,
elaborate
on
gene-editing
tools,
their
configurations,
assorted
delivery
methods,
while
delving
into
present
state
nanomaterial-facilitated
interventions
spectrum
Subsequently,
expound
its
deployment
biomedicine,
focusing
research
advances
diagnosis
conditions
against
backdrop
coronavirus
disease
2019
pandemic.
Finally,
summarize
extant
lacunae
current
delineate
prospects
advancement
this
domain.
holistic
approach
augments
pioneering
solutions
treatment,
thereby
endowing
patients
with
efficacious
personalized
therapeutic
alternatives.
International Journal of Molecular Sciences,
Год журнала:
2023,
Номер
24(19), С. 14679 - 14679
Опубликована: Сен. 28, 2023
In
the
last
few
decades,
RNA-based
drugs
have
emerged
as
a
promising
candidate
in
treatment
of
various
diseases.
The
introduction
messenger
RNA
(mRNA)
vaccine
or
therapeutic
agent
enables
production
almost
any
functional
protein/peptide.
key
to
applying
therapy
clinical
trials
is
developing
safe
and
effective
delivery
systems.
Exosomes
lipid
nanoparticles
(LNPs)
been
exploited
vehicles
for
drug
delivery.
This
review
discusses
feasibility
exosomes
LNPs
mRNA
Cancer/testis
antigens
(CTAs)
show
restricted
expression
normal
tissues
widespread
cancer
tissues.
Many
these
CTAs
sera
patients
with
cancers.
These
characteristics
make
them
excellent
targets
immunotherapy.
summarizes
roles
life
processes
current
studies
on
mRNAs
encoding
CTAs.
Clinical
present
beneficial
effects
highlight
employing
mRNA-LNPs
